IKT (Inhibikase Therapeutics) Beta: 0.4881 (As of Jun. 25, 2026)


IKT Inhibikase Therapeutics Inc IKT
36 GF Score
Price $1.88
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Beta?

Inhibikase Therapeutics IKT -1.06% 36 Beta is 0.4881 as of Jun. 25, 2026. GuruFocus rates IKT with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Inhibikase Therapeutics's Beta is 0.4881.


Inhibikase Therapeutics  (NAS:IKT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Inhibikase Therapeutics Beta Related Terms


Inhibikase Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics Beta Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.23 1.42 0.65

Inhibikase Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 0.56 0.53 0.65 0.48

IKT vs NKTX, CAMP, NERV: Beta Comparison

For the Biotechnology subindustry, Inhibikase Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibikase Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Beta falls into.


IKT
36GF Score
Inhibikase Therapeutics Inc IKT
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4881 mean?
Inhibikase Therapeutics (IKT) has a Beta of 0.4881 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Beta too high?
Inhibikase Therapeutics' current Beta is 0.4881. Overall, Inhibikase Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Beta compare to NKTX and CAMP?
Inhibikase Therapeutics' Beta of 0.4881 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Beta is 0.4881. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Beta of 0.4881. The current Beta is 0.4881. Inhibikase Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Beta is 0.4881 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
36GF Score

Get the complete analysis for IKT

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.88
Price